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diameter. A stereotactic biopsy is made and the AA is diagnosed. Surgery is dismissed because of eloquent areas commitment.
STUPP scheme starts: RT, 60Gy, 200 cGy/fraction over tumor volume+margin and temozolomide (TMZ) (75mg/m2) concurrent
and adjuvant. After the ﬁrst appreciation of the treatment response by brain MRI, the partial response of the lesson is objective
with reduction of more than the 50% of its volume. Nowadays, he has 48 months of tracing and 46 cycles of adjuvant TMZ, with
lesson stabilization. He has presented toxicity at CNS level grade I and gastrointestinal levels I and II (according the RTOG grades).
Conclusion. The role of adjuvant QT in this type of tumor is not well deﬁned, if no signiﬁcant toxicity, might consider prolonging
administration if such cycle thereby maintaining the stabilization of the tumor. It would be necessary to conduct studies that
could prove this hypothesis.
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Summary. 48 year old male patient diagnosed of nasopharyngeal squamous carcinoma poorly differentiated stage IV for bone and
liver involvement, MIB 40%, positive for EBV by EBER, AE1-AE3 panqueratinas, 1, 10, 5 and 14 keratines. Treatment was started
with concurrent RT (DT: 70Gy) and cisplatin 75mg/m2 on September 23, 2010. At the end of treatment he showed a complete
metabolic radiological response of primary tumor, and partial response of bone lesions by PET CT. He continued treatment with
palliative cisplatin (60mg/m2 D1/28)/5 FU (800mg/m2 D1–5/28d ic), receiving 8 cycles, and getting stable disease until September
2011, when made clear important lung, bone and liver progression. He referred important dorsal pain poorly controlled with
analgesic for what was planned a new palliative RT treatment on D7–D10. New treatment was began on October 5, 2011 with
cetuximab (250mg/m2/sem)/taxol (80mg/m2/sem) weekly getting partial response in lung, liver and bone paradoxical response
with clear clinical beneﬁt, without NRL symptoms. In April 2012 new liver and bone progression appears so we started treatment
with gemcitabine 800mg/m2 every 14 days and zoledronic acid. In August 2012 new progression, initiating treatment with
intravenous methotrexate 30mg/m2 weekly. He introduced worse irradiated lumbosacral pain so we increased opioid treatment
with MST until 40mg/12h without improvement and visualizing total sacro occupying lesion, new treatment is planned on sacral
with RT DT 30Gy. In November 2012 new progression at multiple levels, he was treated with vinorelbine (25mg/m2 D1, 8/21) in
compassionate use. He died on 31/12/12. Approximate median survival of nasopharyngeal carcinoma st IV of 10 months.
Patient survival. 26 months.
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Summary. 68 year old male patient with severe COPD managed with oxygen therapy, who initiated progressive dysphagia for
solids in March 2007. Digestive endoscopy was performed ﬁnding a medium esophageal tumor with positive biopsy for squamous
carcinoma. TAC extension study visualized a mass in the middle third of the esophagus, 7 cm length and adjacent pathological
adenopathywithout distance involvement. Considering it inoperable for a high anesthetic risk,we startedQT treatment (cisplatin
– 5 FU) and concurrent RT 3D over an esophageal tumor volume and nodal chains, total dose of 45Gy (5×180 cGy) concluding on
July 2007. Adjuvant QT is completed until September 2007 Excellent treatment tolerance improving the dysphagia progressively.
The digestive endoscopy after treatment viewed mass persistence so we performed two sessions with Ir 192 brachytherapy
(5Gy) Evolution: On April 29, 2008, we objectiﬁed two brain metastases managed RT holocraneal, DT: 32.5Gy (13×250 cGy) and
subsequent radiosurgery on both lesions administered 15Gy to isodose of 85% in September 2008. Without ﬁnding disease
progression in successive controls. Since July 2012 the patient presented progressive deterioration with episodes of dizziness,
nausea and instability, TAC is performed on August 2012 ﬁnding important perilesional edema, initiating oral corticosteroids
treatment with progressive improvement. He has requested steroid treatment with intermittent pattern with signiﬁcant side
effects (muscle atrophy, irritability, hypertension) being impossible the total removal for NRL progressive deterioration Current
status: In January 2013 a RM was done, coming upon right temporal radionecrosis. Due to the dependence to corticosteroid
treatment and severe side effects we start bevacizumab in compassionate use. Disease-free interval 4 years from diagnosis of
brain metastases.
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